LENZ Therapeutics Reports $1.6M Q4 VIZZ Sales, Files EMA MAA
LENZ generated $1.6 million in Q4 2025 revenue from over 20,000 VIZZ prescriptions and has topped 45,000 paid scripts through Q1 2026 across more than 10,000 prescribers. The company holds $292.3 million in cash, is expanding its sales force to 117 territories by Q2 and has filed an EMA MAA.
1. Commercial Launch and Early Revenue
LENZ initiated first commercial sales of VIZZ in October 2025 and recorded $1.6 million in product revenue from over 20,000 filled prescriptions in Q4 2025. Through the end of Q1 2026, total paid prescriptions exceeded 45,000, underscoring rapid early adoption.
2. Prescriber Uptake and Consumer Campaign
Broad uptake by eye care professionals drove growth, with more than 6,500 unique prescribers in Q4 2025 rising to over 10,000 through Q1 2026, and over 55% writing multiple scripts. The January 2026 “Make it VIZZable” direct-to-consumer campaign featuring Sarah Jessica Parker boosted website traffic by up to 10×.
3. Sales Infrastructure Expansion
To support growing demand, LENZ expanded its sales organization from 88 to 117 territories, with full deployment expected in Q2 2026. The increase will enhance field coverage and frequency of engagement with eye care professionals.
4. Regulatory Submissions and Financial Position
In March 2026 LENZ submitted a Marketing Authorization Application to the European Medicines Agency and has filings in Thailand, Singapore, South Korea and China. The company also secured a Middle East commercialization partnership and reported $292.3 million in cash alongside $17.5 million in ex-US license revenue.